Amgen Inc.'s next CEO says he expects revenue to grow this year as sales pick up for some recently launched products and the company expands operations overseas.
Chief Operating Officer Robert A. Bradway is to succeed current Chief Executive Kevin Sharer this May as head of the world's largest biotech company.
Bradway tells analysts the Thousand Oaks, Calif., company's performance was "solid across the board" last year. He says he believes cash flow and earnings per share will rise this year and says Amgen will continue buying back its stock.
Bradway also says positive results from late-stage studies expected for several drugs in the next couple years could lead to higher sales in the future.
Bradway is speaking Monday at the J.P. Morgan Global Healthcare Conference in San Francisco.